We are developing a method for detecting specific microRNAs produced by different types of cancer cells, enabling the ultra-early detection of cancer. Despite advancements in medical technology that allow for effective treatment when cancer is detected early, a significant number of people still succumb to cancer. Unfortunately, the current national health screening system has its limitations, and as a result, early detection of cancer remains a challenge.
To address this issue, we are focusing on utilizing a substance called microRNA, which is generated by cancer cells and can be found in the bloodstream. By conducting genetic testing on this microRNA, we aim to identify even the smallest cancer cells, facilitating ultra-early detection. Our goal is to incorporate this method into routine medical check-ups and corporate health assessments, making cancer screening easily accessible.
Currently, there are existing early cancer detection services that utilize microRNAs from organisms like nematodes or urine. However, these services face challenges in terms of accuracy and high costs. Our approach, which involves directly detecting microRNAs from blood samples, offers both a non-invasive option and the potential for high accuracy at an affordable price.
Furthermore, we are establishing a framework to approach patients through medical institutions intentionally. This approach not only enhances reliability, particularly when combined with the psychological aspect of blood collection, but also makes it more acceptable to both medical professionals and patients. We believe this approach offers advantages in terms of accuracy, cost-effectiveness, and reliability.
Our primary target audience includes elderly individuals and patients with underlying health conditions who are at a higher risk of developing cancer. By integrating our microRNA-based test with regular blood tests conducted at medical institutions, we can directly reach those individuals who are most in need of cancer screening. Additionally, we plan to introduce this method into corporate health assessments, aiming to spread cancer screening awareness among the working-age population.
We are currently preparing for clinical studies to validate the effectiveness and established methodology of our test in collaboration with university hospitals. Our aim is to have this service available by the spring of 2024.